August 22, 2025: Tennis champion Serena Williams has revealed that a GLP-1 medication helped her lose 31 pounds (14 kilograms) after the birth of her second daughter, Adira, in 2023. In an interview with Vogue, Williams explained that diet and exercise alone were not enough to reach her weight goals.
Williams, now a spokesperson for telehealth provider Ro, which offers GLP-1 medications like Zepbound and Wegovy, described how the drug helped control her appetite and maintain fullness for longer periods. She stressed that using medical support for weight management is a valid choice and should not be stigmatized.
“Sometimes your body requires assistance beyond diet and exercise,” Williams said. “Seeking help when needed is responsible and should be normalized.”
GLP-1 medications, originally developed for type 2 diabetes, have become popular for weight management because they slow digestion and help regulate hunger. Health experts warn, however, that they can cause side effects such as nausea or digestive issues, and in rare instances, more serious complications. Early 2025 reports from the UK cited 85 deaths potentially linked to these treatments, highlighting the importance of medical supervision.
Williams’ openness about her experience has reignited public discussion on medical interventions for weight loss, particularly after childbirth. Her candid account encourages others to consider professional guidance when facing challenges with body weight, emphasizing that seeking support is a strong and informed choice.
By sharing her journey, Williams aims to promote honest conversations about health, wellness, and body image, while advocating for safe and effective use of medical treatments alongside lifestyle efforts.
